Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • hollystephens723
    Member
    • Dec 2018
    • 36

    #1

    Reminder for the FDA Open Data Adverse Event Anomalies Challenge

    As a friendly reminder for those of you participating in the precisionFDA Gaining New Insights by Detecting Adverse Event Anomalies Using FDA Open Data Challenge, you have nine days left before the submission period closes on March 13th.

    For ease of access, openFDA data files can now be downloaded automatically by parsing this JSON file. Please also note that providing code is no longer required for a valid final submission. Selected contributors will be invited to participate in a panel at the Modernizing FDA’s Data Strategy public meeting. We are also pleased to announce that the Journal of the American Medical Informatics Association (JAMIA) supports the submission of a paper describing the challenge and the insights that emerge from it.

    If you are interested in learning more about how FDA is modernizing its data strategy, please attend the Modernizing FDA’s Data Strategy public meeting on March 27th. The meeting will also be streamed virtually for those who don’t live in the DC area!

    We are very excited to see what Anomalies you find!

Latest Articles

Collapse

  • SEQadmin2
    16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
    by SEQadmin2




    NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
    Yesterday, 06:46 AM
  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-28-2026, 09:57 AM
0 responses
25 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-28-2026, 09:51 AM
0 responses
15 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
71 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
48 views
0 reactions
Last Post SEQadmin2  
Working...